6 recruiting, 2 not yet recruiting. 2 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Bladder Cancer (BC): new trials by email Literature Review of Bladder Cancer (BC) trials Research Report on Bladder Cancer (BC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BL-M07D1 (Trastuzumab Brengitecan T-bren) vs Standard of Care Platinum-based Chemotherapy (PBC) for HER2-expressing Metastatic Urothelial Cancer After Progression on Anti-PD-(L)1-based Therapy T-Bren, Dose level 1, T-bren, Dose level 2, Gemcitabine + Platinum Based Chemotherapy (Cisplatin or Carboplatin) - Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Recruiting | SystImmune Inc. | 520 | 2026-09-01 | 2026-10-13 |
| Feasibility of HISA During TURBT for NMIBC HISA - Bladder Cancer, Bladder (Urothelial, Transitional Cell) Cancer Resectable (Pre-Cystectomy) | Not applicable | Not yet recruiting | CAMC Health System | 40 | 2026-08-15 | 2026-09-14 |
| Trop2-Targeted NIR-II Fluorescent Probe for Identifying Bladder Cancer in Ex Vivo Bladder Samples TTP-ICG fluorescent probe - Bladder Cancer (BC), Urothelial Carcinoma (UC) | Phase 2 | Recruiting | Yunnan Cancer Hospital | 30 | 2026-08-01 | 2026-09-30 |
| Local Radiotherapy for Urinary Bladder Cancer in Patients Not Eligible for Curative Treatment Local hypo fractionated adaptive radiotherapy and Standard of Care, Standard of Care (Investigator Choice) - Bladder Cancer (BC) | Not applicable | Recruiting | Umeå University | 248 | 2026-06-03 | 2026-06-09 |
| Outcomes of Definitive Radiotherapy for Bladder Cancer Radiotherapy followed by chemotherapy - Bladder Cancer (BC) | Not yet recruiting | Sohag University | 300 | 2026-04-01 | 2026-03-31 | |
| Trop2-targeting NIR-II Molecular Probe for Guided Identification of Non-Muscle-Invasive Bladder Cancer TTP-ICG incubation solution - Bladder Cancer (BC) | Recruiting | Yunnan Cancer Hospital | 40 | 2025-01-17 | 2026-09-02 | |
| Safety, Tolerability, and Preliminary Efficacy of KD01 Via Intravesical Instillation in Bladder Cancer (BC) KD01(the recombinant oncolytic adenovirus) - Bladder Cancer (BC) | Phase 1 | Recruiting | Tongji Hospital | 29 | 2024-11-04 | 2026-01-22 |
| Non-invasive Urinary Genomics-Based Risk Assessment for Early Urothelial Carcinoma Diagnosis Urothelial Carcinoma (UC), Upper Tract Urothelial Carcinoma | Recruiting | Henan Provincial People's Hospital | 800 | 2019-10-08 | 2026-07-02 |
Urinary Bladder Neoplasms (8) · Carcinoma, Transitional Cell (2) · Disease (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Female Urogenital Diseases (8) · Female Urogenital Diseases and Pregnancy Complications (8) · Male Urogenital Diseases (8) · Neoplasms by Site (8) · Urinary Bladder Diseases (8) · Urogenital Diseases (8) · Urogenital Neoplasms (8) · Urologic Diseases (8) · Urologic Neoplasms (8) · Neoplasms (7) · Carcinoma (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Carboplatin (1) · Cisplatin (1) · Gemcitabine (1) · Platinum Compounds (1) · Standard of Care (1)
Yunnan Cancer Hospital (2) · CAMC Health System (1) · Henan Provincial People's Hospital (1) · Sohag University (1) · SystImmune Inc. (1) · Tongji Hospital (1) · Umeå University (1)
China (4) · United States (2) · Egypt (1) · Sweden (1)
Jimmy Liu Zhao, MD, PhD (1) · Michael G Stencel, DO (1) · Zhifeng Wang, PhD (1)
U54GM104942 (1)